BROWSE·page 9 of 602

Browse EX-10 agreements

7,218 matching material contract exhibits.


EX-10.2

GigCapital8 Corp.

***SPONSOR SUPPORT AGREEMENT ***

This SPONSOR SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of October 8, 2026, by and among GigAcquisitions8 Corp., a Cayman Islands exempted company (“Sponsor”), GigCapital8 Corp., a Cayman Islands exempted company (“SPAC”), Quantisimo Holdings Corp., a BVI business company limited by shares (“PubCo”) and Quantisimo Corp, a BVI business company (the “Company”). Capitalized terms used but not defined herein have the meanings assigned to them in the Agreement and Plan of Merger by and among SPAC, PubCo, the Company and the other parties thereto, dated as of October 8, 2026 (as may be amended from time to time, the “Merger Agreement”).

…

EX-10.2·8-K·CIK 2080019·ACC 0001193125-26-419728·Filed Oct 13, 2026, 08:00 ET

EX-10.1

GigCapital8 Corp.

***SHAREHOLDER SUPPORT AGREEMENT ***

This Shareholder Support Agreement (this “Agreement”) is entered into on October 8, 2026, by and among GigCapital8 Corp., a Cayman Islands exempted company (“SPAC”), Quantisimo Holdings Corp., a newly formed business company with limited liability incorporated under the laws of the British Virgin Islands (“PubCo”), Quantisimo Corp., a business company with limited liability incorporated under the laws of the British Virgin Islands (the “Company”), and WISeQey Corp and SealSQ Corp, each a business company limited by shares incorporated under the laws of the British Virgin Islands (each a “Holder” and a “Company Shareholder” and together, the “Holders” and the “Company Shareholders”). SPAC, PubCo, the Company, and the Company Shareholders are sometimes collectively referred to herein as the “Parties,” and each of them is sometimes individually referred to herein as a “Party.” Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

…

EX-10.1·8-K·CIK 2080019·ACC 0001193125-26-419728·Filed Oct 13, 2026, 08:00 ET

EXECUTION VERSION

LETTER AGREEMENT

October 12, 2026

Reference is made to that certain letter agreement dated January 29, 2026 relating to the initial public offering of M Evo Global Acquisition Corp II, a Cayman Islands exempted company (the “Company”), by and among the Company, the sponsor and the insiders party thereto, a copy of which is attached hereto as Exhibit A (the “Existing Letter Agreement”). This letter agreement (this “Letter Agreement”) is executed in connection with the appointment of Richard Majlinder (the “Director”) to the Company’s board of directors. This Letter Agreement is a separate agreement between the Director and the Company and does not amend the Existing Letter Agreement or make the Director a party thereto. Subsequent amendments to the Existing Letter Agreement shall not affect the terms incorporated into this Letter Agreement unless the Director and the Company otherwise agree in writing. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Existing Letter Agreement.

…

EX-10.1·8-K·CIK 2087361·ACC 0001213900-26-108743·Filed Oct 13, 2026, 08:00 ET

EXECUTION VERSION

INDEMNITY AGREEMENT

October 12, 2026

Reference is made to that certain Indemnity Agreement, dated as of January 29, 2026, by and between M Evo Global Acquisition Corp II, a Cayman Islands exempted company (the “Company”), and the undersigned indemnitees thereto, a copy of which is attached hereto as Exhibit A (the “Existing Indemnity Agreement”). This indemnity agreement (this “Indemnity Agreement”) is executed in connection with the appointment of Richard Majlinder (the “Director”) to the Company’s board of directors. This Indemnity Agreement is a separate agreement between the Director and the Company and does not amend the Existing Indemnity Agreement or make the Director a party thereto. Subsequent amendments to the Existing Indemnity Agreement shall not affect the terms incorporated into this Indemnity Agreement unless the Director and the Company otherwise agree in writing. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Existing Indemnity Agreement.

…

EX-10.2·8-K·CIK 2087361·ACC 0001213900-26-108743·Filed Oct 13, 2026, 08:00 ET

EX-10.1

CDT Equity Inc.

Senior Secured Convertible Note

** **

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY THIS SECURITY.

Original Issue Date: October 6, 2026 Funding Amount $ 5,000,000
Final Maturity Date: March 24, 2027 Original Principal Amount: $ 6,750,000

CDT EQUITY INC.

…

EX-10.1·8-K·CIK 1896212·ACC 0001493152-26-046738·Filed Oct 13, 2026, 08:00 ET

PAID-IN-FULL ACKNOWLEDGMENT

Unsecured Revolving Line of Credit

Date: October 9, 2026

Lender: Larry Powalisz, Chief Executive Officer

Borrower: Adia Med, Inc. (and its relevant subsidiaries, as applicable)

Original Facility Date: June 30, 2024

Acknowledgment

Reference is made to the unsecured revolving line of credit facility originally dated June 30, 2024, as increased most recently to a commitment of $1,000,000, bearing interest at 6% per annum calculated daily, between Larry Powalisz, as lender, and Adia Med, Inc., as borrower.

The Lender acknowledges receipt and application of the following payments from the Borrower:

…

EX-10.1·8-K·CIK 1160420·ACC 0001683168-26-007770·Filed Oct 13, 2026, 07:46 ET

EXHIBIT 10.1

Select Water Solutions, Inc.

Execution Version

| |

…

EX-10.1·8-K·CIK 1693256·ACC 0001104659-26-115262·Filed Oct 13, 2026, 07:40 ET

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

** **

PROMISSORY NOTE

** **

Principal Amount: US$8,253.03

Dated: October 7, 2026

New York, New York

…

EX-10.1·8-K·CIK 2000410·ACC 0001213900-26-108714·Filed Oct 13, 2026, 07:30 ET

EX-10.2

Mueller Water Products, Inc.

MUELLER WATER PRODUCTS, INC.

October 2, 2026

Mike Morgan - Offer of Employment

Dear Mike,

On behalf of Mueller (“Company”), I am very pleased to extend you an offer to join the Company as Executive Vice President, Finance, effective October 28, 2026, and Executive Vice President and Chief Financial Officer, effective upon filing of our FY2026 Annual Report, which anticipated filing date is November 18, 2026. As you will appreciate, this two-step process is driven by securities requirements and will not impact your compensation or responsibilities. In your role you will be reporting directly to me.

Mike, I am excited about the opportunity to have you join our executive leadership team. We are confident that your experience, leadership and track record will be instrumental as we execute Mueller’s strategy and continue to strengthen our financial and operational performance. I look forward to having you as a key partner to me, the Board and our leadership team as we enter Mueller’s next phase of profitable growth and value creation.

…

EX-10.2·8-K·CIK 1350593·ACC 0001350593-26-000038·Filed Oct 13, 2026, 07:04 ET

EX-10.1

Mueller Water Products, Inc.

TRANSITION AGREEMENT

This Transition Agreement (this “Agreement”) is entered into as of October 12, 2026 (the “Effective Date”) by and between Melissa Rasmussen (the “Executive”) and Mueller Water Products, Inc., a Delaware corporation (the “Company”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Company’s Executive Severance Plan dated January 1, 2020, as amended (the “Plan”).

WHEREAS, the Executive currently serves as the Senior Vice President and Chief Financial Officer of the Company;

WHEREAS, the Executive is a participant in the Plan;

WHEREAS, the Executive and the Company desire to transition the Executive to the role of Senior Advisor and resolve any outstanding matters related to the Executive’s subsequent termination of employment with the Company.

NOW, THEREFORE, for the promises and covenants set forth herein and for such other good and valuable consideration, the receipt of which is hereby acknowledged, the Executive and the Company enter into this Agreement on the following terms and conditions:

…

EX-10.1·8-K·CIK 1350593·ACC 0001350593-26-000038·Filed Oct 13, 2026, 07:04 ET

Execution Version THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. NOTHING CONTAINED IN THIS RESTRUCTURING SUPPORT AGREEMENT SHALL BE AN ADMISSION OF FACT OR LIABILITY OR, UNTIL THE OCCURRENCE OF THE AGREEMENT EFFECTIVE DATE ON THE TERMS DESCRIBED HEREIN, DEEMED BINDING ON ANY OF THE PARTIES HERETO. THIS RESTRUCTURING SUPPORT AGREEMENT IS THE PRODUCT OF SETTLEMENT DISCUSSIONS AMONG THE PARTIES HERETO. ACCORDINGLY, THIS RESTRUCTURING SUPPORT AGREEMENT IS PROTECTED BY RULE 408 OF THE FEDERAL RULES OF EVIDENCE AND ANY OTHER APPLICABLE STATUTES OR DOCTRINES PROTECTING THE USE OR DISCLOSURE OF CONFIDENTIAL SETTLEMENT DISCUSSIONS. THIS RESTRUCTURING SUPPORT AGREEMENT DOES NOT PURPORT TO SUMMARIZE ALL OF THE TERMS, CONDITIONS, REPRESENTATIONS, WARRANTIES, AND OTHER PROVISIONS WITH RESPECT TO THE TRANSACTIONS DESC

…

EX-10.1·8-K·CIK 1898496·ACC 0001213900-26-108700·Filed Oct 13, 2026, 07:01 ET

EXHIBIT 10.5

ADC Therapeutics SA

AMENDMENT NO. 2 TO PURCHASE AND SALE AGREEMENT

This Amendment No. 2 to Purchase and Sale Agreement (this “Amendment”), dated as of October 7, 2026, is made and entered into by and between ADC THERAPEUTICS SA, a Swiss *société anonyme *(the “Seller”), and the entities managed by Healthcare Royalty Management, LLC listed on the signature pages hereto and on Exhibit F to the Agreement (collectively, the “Buyer”); provided that, for purposes of this Amendment and the Amendment No. 1 Warrants, “Buyer” shall include each Person executing this Amendment in its capacity as a Buyer or Warrantholder.

RECITALS:

WHEREAS, the Seller and the Buyer are parties to that certain Purchase and Sale Agreement, dated as of August 25, 2021 (the “Agreement”);

WHEREAS, the Buyer has previously paid the Closing Price and the EMA Milestone Payment, comprising an aggregate Purchase Price of $300,000,000 in total;

…

EX-10.5·8-K·CIK 1771910·ACC 0000950103-26-015465·Filed Oct 13, 2026, 06:26 ET